Latest Press Releases
![GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson’s Formulation With Endopure Life Sciences](https://cdn.nwe.io/files/x/b8/c7/5d2c2a4a812f0b817473bf034a30.jpg)
GB Sciences’ Licensing Deal with Endopure Life Sciences will also include Rights to Develop and Market GB Sciences’ Cannabinoid-based Treatments for a Suite of Neurological Disorders
![Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland®](https://cdn.nwe.io/files/x/55/6c/c9689b248a8302ced9405c812148.jpg)
Tune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences’ cannabinoid-based medicine for the treatment of Parkinson’s disease.
![Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge](https://cdn.nwe.io/files/x/ae/79/979e040c668e3af85786da0f5262.jpg)
The Parkinson's disease market is expected to grow to $12.8 billion by 2028.
![GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China](https://cdn.nwe.io/files/x/c5/a6/d03b72f87ab93bd45070aea8d949.jpg)
According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.
![Successful 2022 Milestones Support Value of Gb Sciences' AI-Enabled Drug Discovery Platform](https://cdn.nwe.io/files/x/45/56/1735531ba77b5fbd36047eb116a0.jpg)
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2023 and key developments from 2022
![Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform](https://cdn.nwe.io/files/x/9a/99/ba32f10d9b5c1778d257eb1e435e.jpg)
Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.
![Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations](https://cdn.nwe.io/files/x/9c/fa/e8904d58ed1afdc1114e65b8118f.jpg)
As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.
![Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients](https://cdn.nwe.io/files/x/1d/40/63c32e3c26de828d6275327bc524.jpg)
As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.
![TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit](https://cdn.nwe.io/files/x/b5/2d/4877bef2c0711a852d101f526114.jpg)
At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences' proprietary PhAROS drug discovery platform.
![Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study](https://cdn.nwe.io/files/x/bb/c3/a621d6db9e47c2c12d23ea10b575.jpg)
Gb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.
![TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference](https://cdn.nwe.io/files/x/fd/81/5bf5ed009d49779034272a0fe0bf.jpg)
Dr. Andrea Small-Howard discusses the company's novel process for developing disease-specific, cannabinoid-based therapeutics.
![Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease](https://cdn.nwe.io/files/x/3a/6e/3a0910e45df78c904e348a8048e9.jpg)
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms
![TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article](https://cdn.nwe.io/files/x/6f/35/67f3714f135f0cb925f77936e91e.jpg)
Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.
![Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™](https://cdn.nwe.io/files/x/85/ff/b79e4a7caf3d8b1f364362b4da2f.jpg)
As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology.
![Gb Sciences Leads Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™](https://cdn.nwe.io/files/x/85/ff/b79e4a7caf3d8b1f364362b4da2f.jpg)
As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology.
![TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit](https://cdn.nwe.io/files/x/8e/c2/0307287a8fe27fbf597e9999918d.jpg)
Dr. Andrea Small-Howard explains that Gb Sciences' multicomponent Parkinson's disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that are more effective when used together than singularly, as demonstrated in an animal model of the disease.
![TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit](https://cdn.nwe.io/files/x/85/02/e7e926405af6266be3515bcaa73e.jpg)
President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future successes
![TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference](https://cdn.nwe.io/files/x/6c/67/9bbf2466e1e391622e9d2032a80e.jpg)
President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-based pain medications.
![FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies](https://cdn.nwe.io/files/x/f5/46/182a1304b6e1525dc49726a8b92b.jpg)
Plant-inspired biopharmaceutical company signs leading contract research organization to help with a go-to-market strategy for its cannabinoid-containing therapy for COVID-related cytokine release syndrome.
![Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge](https://cdn.nwe.io/files/x/d5/2d/05cedffb8afba383e441f24c16cf.jpg)
Biopharmaceutical research company's plant-inspired formulations entering final stages before first-in-human clinical trials
![Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article](https://cdn.nwe.io/files/x/28/bd/c55afeb4f10c69ebb857fbb07359.jpg)
On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences' proprietary, time-released, oral nanoparticle technology improved the efficacy of cannabis-based terpenes in modulating a known pain receptor in this study.
![UPDATE: Gb Sciences Issues Shareholder Letter](https://cdn.nwe.io/files/x/16/cb/9bcad2a1b58369c15c44f0f95743.jpg)
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021
![Gb Sciences Issues Shareholder Letter](https://cdn.nwe.io/files/x/16/cb/9bcad2a1b58369c15c44f0f95743.jpg)
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021
![Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis](https://cdn.nwe.io/files/x/fa/cf/47921f3fbb05d727375811ddcc47.jpg)
This new patent covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis.
![Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment](https://cdn.nwe.io/files/x/31/ea/b3bbd744a893c346807df027298a.jpg)
Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cannabis Business Times' and 'Hemp Grower'
![Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility](https://cdn.nwe.io/files/x/bd/9d/02fccd5e3e700ce036cd99b89f74.jpg)
The sale will accelerate the development of Gb Sciences' proprietary Parkinson's disease and COVID-related Cytokine-Release Syndrome therapies
![Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives](https://cdn.nwe.io/files/x/fb/e1/63ec6e82b7b6993a3737cb559e34.jpg)
Biopharmaceutical research company leverages positive data on its cannabinoid-containing mixtures to develop new cytokine release syndrome therapies
![Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships](https://cdn.nwe.io/files/x/f0/ba/60bc037b2a401866c0646831f64d.jpg)
Biopharmaceutical research company pursues faster route for drug discovery using PhAROS™, Gb Sciences' AI-enabled drug discovery platform, and through efficiency in their drug development pipeline leveraging strong relationships
![Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety](https://cdn.nwe.io/files/x/4b/41/9d8982cd31a7cf52bcf442a16dea.jpg)
The biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of Canada.
![Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation](https://cdn.nwe.io/files/x/d1/a0/e649f9b0be535f9163fc15e32459.jpg)
Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixtures as anti-inflammatory therapies for hyperinflammatory conditions associated with COVID-19 and other life-threatening inflammatory conditions.
![Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference](https://cdn.nwe.io/files/x/01/32/981dd6bd19c0cd1d0aeb7828b1f9.jpg)
Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Monday, September 13.
![GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform](https://cdn.nwe.io/files/x/11/e5/4c62c8fddb14b82d4b78ca2a46c9.jpg)
GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain inspired by a family of pepper plants used in traditional medicines around the world.
![GB Sciences Using AI Technology in Plant-Based Drug Discovery Research](https://cdn.nwe.io/files/x/01/18/697d5e694df7bcc9d3366aabcec5.jpg)
Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants.
![Gary Herman Joins GB Sciences' Subsidiary GbS Global Biopharma as Advisory Director](https://cdn.nwe.io/files/x/e1/97/ef43090e89286f7bf98282803576.jpg)
Herman will bring his experience as an investor in undervalued growth companies to this role as Advisory Director
![GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President](https://cdn.nwe.io/files/x/a9/71/7b0daa86afbca1ed3b7d029c7037.jpg)
The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc.
![GB Sciences Featured & Speaking at the SACHS Associates' 4th Annual Neuroscience Innovation Forum](https://cdn.nwe.io/files/x/b1/f5/b8b7b1d105a0caad463ee05836ba.jpg)
Dr. Andrea Small-Howard will be speaking as a part of the live Pain, Migraine & Addiction Panel on April 29 at 11:50 a.m. EDT, and she will be presenting the company during the 20-minute SPOTLIGHT SHOWCASE.
![GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals](https://cdn.nwe.io/files/x/9a/e3/44e25dfdd990d3e52f893cace84e.jpg)
Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM).
![GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform](https://cdn.nwe.io/files/x/fb/ed/adfa4d759f895253f31d9118838b.jpg)
GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability allows researchers to reduce the time and money required for novel, plant-based combination drugs to get to market. This is the intersection of hard science, plant-based medicine, and solid business practices.
![GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief](https://cdn.nwe.io/files/x/62/88/7d9ed1cd10aee9572a8b77f66f5c.jpg)
GB Sciences and their Spanish research partners at the Universidad de Sevilla (USE) have created terpene-containing nanoparticles. These first of their kind nanoparticles are central to GB Sciences' time-released pain formulations that are currently in animal trials at the NRC Canada, in preparation for an IND-filing for a US FDA-registered clinical trial.
![GB Sciences Begins Proof of Concept Studies with Michigan State University for the Treatment of Cytokine Release Syndrome](https://cdn.nwe.io/files/x/e8/df/4ec3ed822d190712696d96321dca.jpg)
If successful, data from this preclinical study would be used as part of the support for an Independent New Drug (IND)-filing with the US Food and Drug Administration (FDA) for the use of GBS' Cannabinoid Containing Complex Mixtures (CCCM™) to treat the potentially-fatal Cytokine Release Syndrome associated with COVID-19 and other dangerous hyperinflammatory conditions.
![GB Sciences Receives $4,150,000 and Completes the Sale of Its Louisiana Operations to Wellcana Plus](https://cdn.nwe.io/files/x/55/80/af834aeba216cdfe174eade51cbf.jpg)
This is the third U.S. patent awarded to GBS's disease-specific Cannabinoid-Containing Complex Mixtures (CCCM™), which further validates GB Sciences' drug discovery platform and strengthens its intellectual property patent portfolio